Novartis

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Biotech

Novartis pays Antares $105M to tackle undruggable cancer targets

Novartis is paying Antares $105 million upfront in a deal worth up to $1.9 billion to tackle historically undruggable cancer targets.

Nick Paul Taylor Jun 24, 2026 9:13am

NVS

Novartis dystrophy data tee up regulatory talks on Avidity drug

Jun 12, 2026 4:30am

glue scissors art supplies

Novartis sticks 2nd deal with Orionis, this one worth up to $1.4B

Jun 10, 2026 8:21am

Berlin Germany Brandenburg Gate

Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm

Brain scan neuroscience

Novartis ‘always looking’ for new ways to shuttle drugs to brain

May 28, 2026 8:44am

Novartis booth at AACR 2026

Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?

May 22, 2026 8:28am